Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zimberelimab + sacituzumab govitecan-hziy + domvanalimab
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination regimen comprising **zimberelimab** (an anti-programmed cell death protein-1 [PD-1] monoclonal antibody), **domvanalimab** (an Fc-silent anti-TIGIT monoclonal antibody), and **sacituzumab govitecan-hziy** (an antibody-drug conjugate targeting Trop-2 and delivering the cytotoxic SN-38 payload). This combination is being tested as investigational first-line therapy in patients with **PD-L1 positive advanced or metastatic triple-negative breast cancer (TNBC)**. The scientific rationale is to combine checkpoint inhibition (PD-1 and TIGIT) with targeted cytotoxicity to enhance anti-tumor immune response and direct tumor cell killing. Zimberelimab and domvanalimab are developed by Arcus Biosciences and Gilead Sciences, while sacituzumab govitecan-hziy is developed by Gilead Sciences. This combination is currently under investigation in a phase II trial[1].
- Brand names
- Trodelvy (sacituzumab govitecan-hziy)
- Other names
- zimberelimabsacituzumab govitecan-hziydomvanalimab
02
Targets
TIGIT (T cell immunoreceptor with Ig and ITIM domains)TACSTD2 (Tumor-associated calcium signal transducer 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on zimberelimab + sacituzumab govitecan-hziy + domvanalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zimberelimab + sacituzumab govitecan-hziy + domvanalimab.